JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study.
Vahid Asnafi,Sandrine Le Noir,Ludovic Lhermitte,Claude Gardin,Faézeh Legrand,Xavier Vallantin,Jean-Valère Malfuson,Norbert Ifrah,Hervé Dombret,Elizabeth Macintyre +9 more
TLDR
This data indicates that suppression of interleukin-10 in B lymphocytes results in down-regulation in infectious, neoplastic, and inflammatory diseases and may also have implications for immunity.Abstract:
cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clinical Microbiology Reviews, 9, 532–562. Lund, F.E. (2008) Cytokine-producing B lymphocytes-key regulators of immunity. Current Opinion in Immunology, 20, 332–339. Moore, K.W., de Waal Malefyt, R., Coffman, R.L. & O’Garra, A. (2001) Interleukin-10 and the interleukin-10 receptor. Annual Review of Immunology, 19, 683–765.read more
Citations
More filters
Journal ArticleDOI
JAKs and STATs in Immunity, Immunodeficiency, and Cancer
TL;DR: A large number of cytokines signal through the JAK–STAT pathway, and normal function of this pathway may lead to a variety of diseases.
Journal ArticleDOI
The molecular basis of T cell acute lymphoblastic leukemia
TL;DR: This review summarizes recent advances in the understanding of the molecular genetics of T-ALL and defines distinct molecular groups ofT-ALL with specific gene expression signatures and clinicobiological features.
Journal ArticleDOI
The genetics and mechanisms of T cell acute lymphoblastic leukaemia
Laura Belver,Adolfo A. Ferrando +1 more
TL;DR: The current understanding of the molecular mechanisms of T-ALL is examined and recent developments in the translation of these results to the clinic are examined.
Journal ArticleDOI
Diagnosis and subclassification of acute lymphoblastic leukemia
TL;DR: This review summarizes how best to identify ALL and the most relevant ALL subsets and describes how to support an optimal risk-oriented therapy and thus increase the curability rate.
Journal ArticleDOI
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.
Takaomi Sanda,Jeffrey W. Tyner,Alejandro Gutierrez,Vu N. Ngo,Jason M. Glover,Bill H. Chang,Arla J Yost,Wenxue Ma,Angela G. Fleischman,Wenjun Zhou,Yandan Yang,Maria Kleppe,Yebin Ahn,Jessica Tatarek,Michelle A. Kelliher,Donna Neuberg,Ross L. Levine,Richard Moriggl,Mathias Müller,Nathanael S. Gray,Catriona Jamieson,Andrew P. Weng,Louis M. Staudt,Brian J. Druker,A. Thomas Look +24 more
TL;DR: RNAi technology is used to identify a novel oncogenic pathway that involves aberrant activation of the TYK2 tyrosine kinase and its downstream substrate, STAT1, which ultimately promotes T-ALL cell survival through the upregulation of BCL2 expression.
References
More filters
Journal ArticleDOI
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
Françoise Huguet,Thibaut Leguay,Emmanuel Raffoux,Xavier Thomas,Kheira Beldjord,Eric Delabesse,Patrice Chevallier,Agnès Buzyn,André Delannoy,Yves Chalandon,Jean-Paul Vernant,Marina Lafage-Pochitaloff,Agnès Chassevent,Véronique Lhéritier,Elizabeth Macintyre,Marie-Christine Béné,Norbert Ifrah,Hervé Dombret +17 more
TL;DR: It is suggested that pediatric-inspired therapy markedly improves the outcome of adult patients with ALL, at least until the age of 45 years, as compared with the previous LALA-94 experience.
Journal ArticleDOI
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia
Elisabetta Flex,Valentina Petrangeli,Lorenzo Stella,Sabina Chiaretti,Tekla Hornakova,Laurent Knoops,Cristina Ariola,Valentina Fodale,Emmanuelle Clappier,Francesca Paoloni,Simone Martinelli,Alessandra Fragale,Massimo Sanchez,Simona Tavolaro,Monica Messina,Giovanni Cazzaniga,Andrea Camera,Giovanni Pizzolo,Assunta Tornesello,Marco Vignetti,Angela Battistini,Hélène Cavé,Bruce D. Gelb,Jean-Christophe Renauld,Andrea Biondi,Stefan N. Constantinescu,Robin Foà,Marco Tartaglia +27 more
TL;DR: It is reported that somatic mutations in JAK1 occur in individuals with acute lymphoblastic leukemia (ALL), and this kinase is pointed to as a target for the development of novel antileukemic drugs.
Journal ArticleDOI
Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia.
Stephen Breit,Martin Stanulla,Thomas Flohr,Martin Schrappe,Wolf-Dieter Ludwig,Gabriele Tolle,Margit Happich,Martina U. Muckenthaler,Andreas E. Kulozik +8 more
TL;DR: The findings indicate that in the context of the ALL-BFM 2000 treatment strategy, NOTCH1 mutations predict a more rapid early treatment response and a favorable long-term outcome in children with T-ALL.
Journal ArticleDOI
NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study.
Vahid Asnafi,Vahid Asnafi,Agnes Buzyn,Sandrine Le Noir,Sandrine Le Noir,Frederic Baleydier,Frederic Baleydier,Arnauld Simon,Kheira Beldjord,Kheira Beldjord,Oumedaly Reman,Francis Witz,T. Fagot,Emmanuelle Tavernier,Pascal Turlure,Thibaut Leguay,Françoise Huguet,Jean-Paul Vernant,Francis Daniel,Marie-Christine Béné,Norbert Ifrah,Xavier Thomas,Hervé Dombret,Elizabeth Macintyre,Elizabeth Macintyre +24 more
TL;DR: It is demonstrated that notCH1 pathway activation by either NOTCH1 or FBXW7 mutation identifies a large group of patients with a favorable outcome that could justify individual therapeutic stratification for T-ALL.
Journal ArticleDOI
Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers
Eun Goo Jeong,Min Sung Kim,Hyo Kyung Nam,Chang-Ki Min,Seok Lee,Yeun-Jun Chung,Nam Jin Yoo,Sug Hyung Lee +7 more
TL;DR: The data indicate that both JAK1 and JAK3 mutations occur in common human cancers and that Jak1 mutation in T-ALL is a frequent event, and suggest that some of the JAK 1 and Jak3 mutations may to be functional and contributes to cancer development, especially to T-all development.
Related Papers (5)
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Jinghui Zhang,Li Ding,Linda Holmfeldt,Gang Wu,Susan L. Heatley,Susan L. Heatley,Debbie Payne-Turner,John Easton,Xiang Chen,Jianmin Wang,Michael Rusch,Charles Lu,Shann Ching Chen,Lei Wei,J. Racquel Collins-Underwood,Jing Ma,Kathryn G. Roberts,Stanley Pounds,Anatoly Ulyanov,Jared Becksfort,Pankaj Gupta,Robert Huether,Richard W. Kriwacki,Matthew Parker,Daniel J. McGoldrick,David Zhao,Daniel Alford,Stephen Espy,Kiran Chand Bobba,Guangchun Song,Deqing Pei,Cheng Cheng,Stefan Roberts,Michael I. Barbato,Michael I. Barbato,Dario Campana,Dario Campana,Elaine Coustan-Smith,Elaine Coustan-Smith,Sheila A. Shurtleff,Susana C. Raimondi,Maria Kleppe,Maria Kleppe,Jan Cools,Kristin A. Shimano,Michelle L. Hermiston,Sergei Doulatov,Kolja Eppert,Elisa Laurenti,Faiyaz Notta,John E. Dick,Giuseppe Basso,Stephen P. Hunger,Mignon L. Loh,Meenakshi Devidas,Brent L. Wood,Stuart S. Winter,Kimberley P. Dunsmore,Robert S. Fulton,Lucinda Fulton,Xin Hong,Chris Harris,David J. Dooling,Kerri Ochoa,Kimberly J. Johnson,John C. Obenauer,William E. Evans,Ching-Hon Pui,Clayton W. Naeve,Timothy J. Ley,Elaine R. Mardis,Richard K. Wilson,James R. Downing,Charles G. Mullighan +73 more
JAK mutations in high-risk childhood acute lymphoblastic leukemia.
Charles G. Mullighan,Jinghui Zhang,Richard C. Harvey,J. Racquel Collins-Underwood,Brenda A. Schulman,Letha A. Phillips,Sarah K. Tasian,Mignon L. Loh,Xiaoping Su,Wei Liu,Meenakshi Devidas,Susan R. Atlas,I-Ming Chen,Robert J. Clifford,Daniela S. Gerhard,William L. Carroll,Gregory H. Reaman,Malcolm A. Smith,James R. Downing,Stephen P. Hunger,Cheryl L. Willman +20 more
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Andrew P. Weng,Andrew P. Weng,Adolfo A. Ferrando,Adolfo A. Ferrando,Woojoong Lee,Woojoong Lee,John P. Morris,John P. Morris,Lewis B. Silverman,Lewis B. Silverman,Cheryll Sanchez-Irizarry,Cheryll Sanchez-Irizarry,Stephen C. Blacklow,Stephen C. Blacklow,A. Thomas Look,A. Thomas Look,Jon C. Aster,Jon C. Aster +17 more